Cizzle Biotechnology Holdings Plc (LSE: CIZ)
Health Care · Biotechnology · GB
£0.01
-29.31% today · -33.9% 1Y
Cizzle Biotechnology Holdings Plc (LSE: CIZ) operates in the Biotechnology industry within the Health Care sector. The company is valued at $5.81M and employs 5 people.
Over the last twelve months the share price has lost 33.9%, trading between 0.01 and 0.04.
Tweenvest scores Cizzle Biotechnology Holdings Plc across four factors: quality 22/100, value 36/100. Its strongest factor is value.
CIZ price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $5.81M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- -0.09
- 52-week high
- £0.04
- 52-week low
- £0.01
- Avg volume (3M)
- —
- Shares outstanding
- 424.96M
- Employees
- 5
- Next earnings
- —
About Cizzle Biotechnology Holdings Plc
Cizzle Biotechnology Holdings Plc specializes in developing an advanced immunoassay diagnostic test. This innovative tool aims to identify the CIZ1B biomarker, facilitating the early detection of lung cancer. The company, previously known as Cizzle Biotechnology Limited, officially changed its corporate identity to Cizzle Biotechnology Holdings Plc in May 2021. Its main operational base is situated in London, United Kingdom.
- ISIN
- GB00BNG2VN02
- Listed since
- May 14, 2021
- Exchange
- London Stock Exchange
- Currency
- GBP
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Bio Green Med Solution, Inc.NasdaqCM: BGMS | $6.02M | $0.91 | +7.10% |
| Acurx Pharmaceuticals, Inc.NasdaqCM: ACXP | $5.98M | $1.14 | -0.44% |
| Niki BioSolutions, Inc.NasdaqCM: NIKI | $5.97M | $2.03 | -49.25% |
| Can-Fite BioPharma Ltd.TASE: CANF | $5.94M | ₪3.04 | -3.00% |
| OLIPASS CorporationKOSDAQ: A244460 | $5.72M | ₩— | — |
| Imunon, Inc.NasdaqCM: IMNN | $5.72M | $1.02 | -5.56% |
| AquaBounty Technologies, Inc.NasdaqCM: AQB | $5.71M | $1.11 | +8.82% |
| NeuroSense Therapeutics Ltd.NasdaqCM: NRSN | $5.68M | $3.07 | -16.12% |
Figures last refreshed Oct 18, 2026.